Daniel Guzmán-Gómez

Daniel Guzmán-Gómez

Auto-generated profile, based on publicly available information

Daniel Guzmán-Gómez

LADISER de Inmunología y Biología Molecular, Facultad de Ciencias Químicas, Universidad Veracruzana (UV), Prolongación de Oriente 6 #1009, Colonia Rafael Alvarado, Orizaba 94340, Veracruz, Mexico

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2015 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
DGDaniel Guzmán-Gómez
Daniel Guzmán-Gómez
ALAracely López-Monteon
Aracely López-Monteon
MLMaría de la Soledad Lagunes-Castro
María de la Soledad Lagunes-Castro
CÁCarolina Álvarez-Martínez
Carolina Álvarez-Martínez
MHManuel Jesús Hernández-Lutzon
Manuel Jesús Hernández-Lutzon
ARAngel Ramos-Ligonio
Angel Ramos-Ligonio
Chagas disease is a parasitic disease caused by the protozoan parasite Trypanosoma cruzi. In Mexico, the burden of the disease is difficult to estimate and improving surveillance for Chagas disease is an important priority. We aimed here at determining the seroprevalence of T. cruzi infection in humans in a rural community in Veracruz. Serum samples (196) were analyzed for T. cruzi infection using five enzyme-linked immunosorbent assay (ELISA) tests: two in-house tests based on crude parasite extract and three commercial ELISA kits. Because of highly discordant results, we further explored the importance of parasite antigens and strains by western-blot analysis. A total of 74 samples (37.7 %) were reactive with at least one ELISA, but discordance among tests was very high. The best agreement was between Chagatest recombinant and Chagatek ELISA (Kappa index = 0.798). The agreement between other combinations of tests ranged from 0.038 to 0.518. Discordant samples were confirmed by western-blot analysis using up to nine parasite strains, giving a seroprevalence of 33.7 %. Commercial tests had a very limited ability to detect T. cruzi infection in the study population. In-house tests based on crude parasite antigens showed a greater sensitivity but were still unable to detect all cases of T. cruzi infection, even when based on a local parasite strain. The high seroprevalence confirmed the hyper-endemicity of T. cruzi infection in the region. Reliable epidemiological surveillance of Chagas disease will require the development of improved diagnostic tests.

1 July 2010 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
ARAngel Ramos-Ligonio
Angel Ramos-Ligonio
ALAracely López-Monteon
Aracely López-Monteon
DGDaniel Guzmán-Gómez
Daniel Guzmán-Gómez
JRJosé Luis Rosales-Encina
José Luis Rosales-Encina
YLYairh Limón-Flores
Yairh Limón-Flores
Eric DumonteilEric Dumonteil
Eric Dumonteil
The state of Veracruz, Mexico, is a well-recognized endemic region for Chagas disease, but the geographic distribution of the disease and its magnitude are still poorly documented. We evaluated the seroprevalence of Trypanosoma cruzi infection in the sanitary jurisdictions of Cordoba and Cosamaloapan in central Veracruz. A total of 654 serum samples from 19 rural localities were tested by using four tests: two enzyme-linked immunosorbent assays, an indirect immunofluorescent, and Western blotting. Overall, 110 (16.8%) of 654 samples were positive for T. cruzi by ≥ 2 tests (95% confidence interval = 14.2–19.9%). The municipality of Tezonapa in the jurisdiction of Cordoba was identified as a potential hyperendemic region with seroprevalence rates ≤ 45% in young children. No cases were detected in the jurisdiction of Cosamaloapan. Further studies should help clarify T. cruzi transmission dynamics in Tezonapa. The magnitude of T. cruzi infection rate in this region calls for the urgent implementation of extensive epidemiologic surveillance and control programs.

19 November 2012 in American Journal of Primatology
Verified
Journal Article
Closed access
PDF file
MRMaría DE Jesús Rovirosa‐Hernández
María DE Jesús Rovirosa‐Hernández
LCLiliana Cortes‐Ortíz
Liliana Cortes‐Ortíz
FGFrancisco García‐Orduña
Francisco García‐Orduña
DGDaniel Guzmán‐Gómez
Daniel Guzmán‐Gómez
ALAracely López‐Monteon
Aracely López‐Monteon
ARAngel Ramos-Ligonio
Angel Ramos-Ligonio

29 August 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ALA. López-Monteon
A. López-Monteon
FGF. S. Gómez-Figueroa
F. S. Gómez-Figueroa
GRG. Ramos-Poceros
G. Ramos-Poceros
DGD. Guzmán-Gómez
D. Guzmán-Gómez
ARAngel Ramos-Ligonio
Angel Ramos-Ligonio
The aim of this study is to estimate the prevalence ofTrichomonas vaginalisandCandida albicansin low-risk patients treated at a first level clinic (primary health care represents the first level of contact of individuals, families, and the community with the system national health). Using a cross-sectional study in patients treated in clinical laboratory of the Sanitary District no. 7 of the city of Orizaba during the months June-July, 252 urine samples were collected for the identification ofT. vaginalisandC. albicansby PCR. Furthermore, we analyzed the sociodemographic characteristics of the studied population. We observed an overall prevalence of 23.41% (95% CI 22.10–24.72) forT. vaginalisand 38.88% (95% CI 37.73–40.03) forC. albicans. There was also presence of coinfection in 14.28% (95% CI 13.10–15.46), which was associated with the presence of pain. Most of the positive cases were observed in women house-maker (80%, 95% CI 50.36–48.98). The results of this study provide evidence that the majority of positive cases observed in the studied population are presented in an asymptomatic form and usually are not associated with any risk factor.

18 July 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MOMercedes Olvera-Valencia
Mercedes Olvera-Valencia
FLFernando Luna
Fernando Luna
JRJoselyn Juarez Reyes
Joselyn Juarez Reyes
ASAlejandro Lopez Saavedra
Alejandro Lopez Saavedra
JCJossimar Coronel
Jossimar Coronel
EPEloy Perez-Yepez
Eloy Perez-Yepez
Sarcomas are heterogeneous mesenchymal tumors, and their pharmacological treatment remains challenging due to the high toxicity and poor efficacy of current therapies. This study aimed to identify common overexpressed kinases in the four most frequent sarcoma subtypes to establish novel therapeutic targets. A bioinformatics approach using patient-derived gene expression data sets identified overexpressed kinases shared across these sarcoma types. Later, BUB1 was determined as the kinase consistently overexpressed across the osteosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma. Moreover, the role of this kinase was further validated through molecular and functional assays, including pharmacological inhibition in cell lines derived from the four sarcoma subtypes. BUB1 inhibition reduced the phosphorylation of AKT and H2A proteins, precluded cell proliferation, and inhibited colony formation in sarcoma cells. Finally, overall survival analysis highlighted a strong correlation between high BUB1 expression and poorer survival rates in sarcoma patients. Altogether, these findings underscore the potential of BUB1 as a therapeutic target and prognostic marker in sarcomas. Targeted inhibition of BUB1 may provide a novel strategy to reduce tumor growth and improve outcomes for patients with bone and soft tissue sarcomas.